Literature DB >> 7320123

Rapid high-performance liquid chromatographic method for the measurement of verapamil and norverapamil in blood plasma or serum.

S C Cole, R J Flanagan, A Johnston, D W Holt.   

Abstract

A simple high-performance liquid chromatographic method for the simultaneous measurement of plasma verapamil and norverapamil concentrations has been developed. The sample (100 microliters) is vortex-mixed for 30 sec with 4 M sodium hydroxide solution, pH 13 (50 microliters), internal standard solution (aqueous 5,6-benzoquinoline, 0.20 mg/l) (50 microliters) and methyl tert.-butyl ether (200 microliters). After centrifugation at 9950 x g for 2 min, a portion (100 microliters) of the resulting extract is analysed on a microparticulate (5 microns) silica column using a methanolic solution of potassium bromide (3.0 mM) and perchloric acid (0.37 mM) as the mobile phase, and the column effluent is monitored by fluorescence detection using an excitation wavelength of 203 nm. A specimen, together with a quality control sample, can be analysed, in duplicate, within 30 min. The limit of accurate measurement of the assay is 2 micrograms/l, and no potential sources of interference have been identified. The method has advantages of speed, small sample requirement and complete resolution of the three major metabolites of verapamil.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7320123     DOI: 10.1016/s0021-9673(00)82087-7

Source DB:  PubMed          Journal:  J Chromatogr


  18 in total

1.  Low-dose verapamil in middle-aged and elderly patients with angina pectoris: no evidence of increased susceptibility to the cardiac effects.

Authors:  J H Ahmed; H L Elliott; P A Meredith; J L Reid
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

2.  Effect of oral verapamil on glibenclamide stimulated insulin secretion.

Authors:  C G Semple; C Omile; K D Buchanan; G H Beastall; K R Paterson
Journal:  Br J Clin Pharmacol       Date:  1986-08       Impact factor: 4.335

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

4.  Pharmacokinetics and pharmacodynamics of two formulations of verapamil.

Authors:  K K Hla; J A Henry; A N Latham
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

5.  Calcium antagonists and endocrine status: lack of effect of oral verapamil on pituitary-testicular and pituitary-thyroid function.

Authors:  C G Semple; J A Thomson; G H Beastall; A R Lorimer
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

6.  Verapamil pharmacokinetics and apparent hepatic and renal blood flow.

Authors:  P A Meredith; H L Elliott; F Pasanisi; A W Kelman; D J Sumner; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

7.  A double blind placebo controlled comparison of verapamil, atenolol, and their combination in patients with chronic stable angina pectoris.

Authors:  I N Findlay; K MacLeod; G Gillen; A T Elliott; T Aitchison; H J Dargie
Journal:  Br Heart J       Date:  1987-04

8.  R-verapamil: pharmacokinetics and effects on PR interval, blood pressure and heart rate.

Authors:  J H Ahmed; J Godden; P A Meredith; H L Elliott
Journal:  Br J Clin Pharmacol       Date:  1993-08       Impact factor: 4.335

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Antiarrhythmic actions of verapamil against ischaemic arrhythmias in the rat.

Authors:  M J Curtis; B A MacLeod; M J Walker
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.